Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Suicidality

Ketamine for Suicidality

147 papers and 74 clinical trials exploring ketamine as a treatment for suicidality.

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
IndicationMore than 727,000 deaths by suicide worldwide each year

Suicidality

Suicidality covers the spectrum of suicidal thoughts, plans and behaviours, and it contributes to more than 727,000 deaths worldwide each year. The strongest evidence for rapidly reducing suicidal thinking is for ketamine and esketamine, and esketamine carries a specific regulatory approval. But even there, a reduction in suicide itself has not been proven, and classic psychedelics remain unproven for suicidality and can carry real risks for people in crisis. This is a research summary, not medical advice.

Full Suicidality profile

Academic Research

147 papers
Paywallindividual

A pilot randomized trial of ketamine for suicidal ideation in a pediatric emergency department

This triple-blind randomised controlled trial (n=15) in adolescents with suicidal ideation in a paediatric emergency department tested whether intravenous ketamine, midazolam or saline could be studied feasibly and safely. Recruitment and follow-up were good, blinding seemed effective, and no serious or unexpected adverse events occurred.

Published
June 3, 2026
Journal
Canadian Journal of Emergency Medicine
Authors
Onikashvili, Y., Burt, H., Meckler, G., Bone, J. N., Hind, T., Sih, K., Sassi, R., Stillwell, K., Black, T., Doan, Q.
Open Accessindividual

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

This randomised, double-blind, placebo-controlled trial (n=50) tested low-dose sublingual buprenorphine after ketamine in adults with major depressive disorder and suicidal thoughts. Buprenorphine led to a greater and longer-lasting reduction in suicidal ideation than placebo, while depression scores were similar and no serious treatment-related side effects occurred.

Published
May 18, 2026
Journal
American Journal of Psychiatry
Authors
Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., Schatzberg, A. F.
Paywallindividual

Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation: An Open-Label Trial

This open-label single-arm trial (n=20) found that a single 25 mg dose of psilocybin with psychological support was linked to rapid and lasting reductions in chronic suicidal thoughts and depression over 12 weeks. No serious adverse events were reported.

Published
May 13, 2026
Journal
Journal of Clinical Psychiatry
Authors
Vaart, A. V. D., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H. A., Aaronson, S. T.
Open Accessindividual

Ketamine addiction following a single sub-anaesthetic ketamine treatment for acute suicidality in a psychiatrically multimorbid patient: case report

This case report describes a 25-year-old woman who developed ketamine addiction after a single sub-anaesthetic intranasal dose given for acute suicidality. She later escalated to daily illicit ketamine use, with cocaine and 3-MMC misuse, leading to financial and housing problems and a suicide attempt when access was stopped.

Published
April 21, 2026
Journal
BJPsych Open
Authors
Roelandt, G. H. J., Strous, J. F. M., Kamphuis, J., Schoevers, R. A., Marijnissen, R. M.
Open Accessindividual

Single dose IV ketamine for adolescent suicidal ideation in the emergency department: a pilot randomized trial

This double-blind, randomised, placebo-controlled pilot trial (n=20) tested a single IV dose of ketamine for suicidal thoughts in adolescents attending the emergency department. It found the study was feasible and well tolerated, but ketamine did not clearly reduce suicidal ideation at 40 minutes, although fewer participants were admitted to hospital at the initial visit.

Published
April 6, 2026
Journal
BMC Psychiatry
Authors
Schlegelmilch, M., Plint, A. C., Barrowman, N., Gray, C., Crawford, T., Kutcher, S. A., Bhatt, M.
Open Accessindividual

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD A Randomized Clinical Trial

In a multicentre, double‑blind, placebo‑controlled phase 2 trial of 65 adults with chronic PTSD, once‑weekly oral TSND‑201 produced significantly greater reductions in clinician‑rated PTSD severity (CAPS‑5; LS mean difference 9.64, P = .01) and improvements in self‑reported symptoms, functioning and depression versus placebo. TSND‑201 was generally well tolerated — common adverse events included headache, decreased appetite, nausea, dizziness and transient blood‑pressure increases — supporting its potential as a rapid‑acting, durable treatment for PTSD.

Published
February 18, 2026
Journal
JAMA Psychiatry
Authors
Jones, A., Warner-Schmidt, J., Kwak, H., Stogniew, M., Mandell, B., Ching, T. H., Stein, M. B., Kelmendi, B.

Clinical Trials

74 trials
Not yet recruitingPhase II

Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

This Phase II randomised, quadruple-masked trial (n=120) will study adults aged 18 to 70 years with borderline personality disorder, treatment-resistant major depressive disorder or bipolar disorder, and suicidal ideation, evaluating whether intravenous ketamine plus dialectical behavioural therapy (DBT) reduces suicidal ideation more rapidly and robustly than midazolam plus DBT. The main purpose is to assess change in suicidal ideation severity from baseline to Day 35 using the Modified Scale for Suicidal Ideation (MSSI). All participants will receive DBT for 6 months, starting before the infusions, with weekly individual sessions and the addition of weekly group sessions from Week 5. The experimental arm will receive six intravenous ketamine infusions over 1 month: the first two at 0.5 mg/kg over 40 minutes, infusions 3 and 4 flexibly dosed at 0.5 mg/kg to 0.75 mg/kg, and infusions 5 and 6 flexibly dosed at 0.5 mg/kg to 0.85 mg/kg. The comparator arm will receive six intravenous midazolam infusions over the same period: the first two at 0.02 mg/kg over 40 minutes, infusions 3 and 4 at 0.02 mg/kg to 0.03 mg/kg, and infusions 5 and 6 at 0.2 mg/kg to 0.035 mg/kg. Participants will also complete hospital visits, remote follow-up by call or videocall, and a range of mood, cognitive and behavioural assessments.

Started
June 1, 2026
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT07569198
RecruitingPhase III

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (AVENUE)

This Phase III, double-blind, randomised, placebo-controlled trial (n=258) will evaluate the efficacy and safety of intranasal esketamine 84 mg in addition to comprehensive standard of care for rapidly reducing symptoms of major depressive disorder (MDD) in adolescent participants aged 12 to 17 with acute suicidal ideation or behaviour. The primary outcome is the change in depressive symptoms measured by the Children's Depression Rating Scale - Revised (CDRS-R) total score at 24 hours post-first dose. Participants will be randomly assigned to receive either intranasal esketamine (84 mg, with potential dose adjustments to 56 mg) plus oral placebo or intranasal placebo plus oral midazolam (0.0625 mg/kg) twice weekly for four weeks. The treatment will occur on specific days, with assessments conducted to monitor the efficacy and safety of the interventions. The trial is sponsored by Janssen Research & Development, LLC, with an estimated start date of January 8, 2026, and a completion date of September 15, 2031.

Started
January 8, 2026
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT07227454
Not yet recruitingPhase II

Ketamine Infusion for Symptomatic Improvement in Severe Borderline Personality Disorder: A Pilot Study (BorderKET)

Open-label, single-group Phase II pilot (n=38) testing two IV ketamine infusions (0.5 mg/kg each, 40 min, at H0 and H24) plus Good Psychiatric Management in adults with severe BPD; primary outcome at day 9 (BSL-23).

Started
November 1, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT07099534
Not yet recruitingPhase NA

A Study on the Rapid Antisuicidal Mechanism and Therapeutic Efficacy Prediction of Ketamine Based on Glu/GABA Metabolism in the Prefrontal-Limbic System Circuit

This non-randomised controlled interventional study (n=199) in China is evaluating the rapid anti-suicidal effects and mechanistic correlates of ketamine in adults aged 18 to 65 with major depressive disorder, with a focus on those with suicidal ideation. Participants are assigned to a major depressive disorder group without suicidal ideation (n=50, no intervention) or a major depressive disorder group with suicidal ideation (n=149) receiving intravenous ketamine. The trial is designed to investigate how ketamine influences glutamate/GABA metabolism within prefrontal-limbic circuit networks, and to identify neuroimaging markers associated with treatment response. The primary outcomes are neuroimaging-based and include comparisons between participants whose suicidal ideation decreases versus those whose ideation remains unchanged, imaging changes within the ketamine-treated group before and after treatment, and neuroimaging features that may predict ketamine’s anti-suicidal effect. Secondary outcomes assess correlations between neuroimaging features and individual symptom scores, including MADRS and HAMD ratings. The study is sponsored by Beijing Anding Hospital, Capital Medical University, and is currently pending. No phase designation or ketamine dose has been provided.

Started
September 20, 2025
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
ChiCTR2500108533
Not yet recruitingPhase III

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

This randomised, double-blind, placebo-controlled Phase III trial (n=60) will investigate the efficacy and safety of subcutaneous ketamine (35-70mg/70kg, twice weekly for four weeks) as an add-on treatment for adolescents experiencing a major depressive episode with suicidal ideation and/or behaviour.

Started
May 1, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06957704
RecruitingPhase II/III

Understanding and Treating Suicidal Ideation With Ketamine

This open-label, Phase II/III trial (n=36) will study the effects of ketamine (0.5 mg/kg IV infused over 40 minutes, four infusions over two weeks) on suicidal ideation in individuals with major depressive disorder (MDD).

Started
April 8, 2025
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06891300

Explore further

Search all Ketamine papers Search all Suicidality trials Full Ketamine profile Full Suicidality profile